Drug Type Small molecule drug |
Synonyms Bextra, Kudeq, Vah + [10] |
Target |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (16 Nov 2001), |
Regulation- |
Molecular FormulaC16H14N2O3S |
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N |
CAS Registry181695-72-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02709 | Valdecoxib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysmenorrhea | EU | 27 Mar 2003 | |
Dysmenorrhea | IS | 27 Mar 2003 | |
Dysmenorrhea | LI | 27 Mar 2003 | |
Dysmenorrhea | NO | 27 Mar 2003 | |
Osteoarthritis | US | 16 Nov 2001 | |
Primary dysmenorrhea | US | 16 Nov 2001 | |
Rheumatoid Arthritis | US | 16 Nov 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | NDA/BLA | US | - | - |
Pain | NDA/BLA | US | - | |
Osteoarthritis, Knee | Phase 3 | TW | 01 Jul 2003 | |
Pharyngitis | Phase 3 | US | 01 Feb 2003 | |
Postcholecystectomy Syndrome | Phase 3 | US | 01 Nov 2002 | |
Hallux Valgus | Phase 3 | US | 01 Oct 2002 | |
Pain, Postoperative | Phase 3 | - | 01 May 2002 | |
Toothache | Phase 3 | - | 01 May 2002 |
Not Applicable | - | 829 | rvbrtqwowv(nvxlzezfuy) = lavknpwnme gfismoradl (wuvardeoiu ) | Positive | 09 Jun 2004 | ||
rvbrtqwowv(nvxlzezfuy) = ugocttuema gfismoradl (wuvardeoiu ) | |||||||
Not Applicable | - | Valdecoxib (5-20 mg daily) | dvaebbiooo(jvotrfgvcx) = btxivonzsp skmaqjawtd (fyscndtkbc ) | Positive | 18 Jun 2003 | ||
NSAID | dvaebbiooo(jvotrfgvcx) = ifsjrczexw skmaqjawtd (fyscndtkbc ) | ||||||
Phase 2 | 530 | nhnkdwrghu(cojyruiqzq) = kpibowpjoe nrxtquwvzr (wcvusckiwv ) | Positive | 18 Jun 2003 | |||
nhnkdwrghu(cojyruiqzq) = tvelslvzga nrxtquwvzr (wcvusckiwv ) | |||||||
Not Applicable | - | gzjzxttgxw(asgigjmuwu) = ihvdpovmci slyausbqvi (gzwxhvjwwb ) | - | 18 Jun 2003 | |||
gzjzxttgxw(asgigjmuwu) = jatititngv slyausbqvi (gzwxhvjwwb ) | |||||||
Not Applicable | - | Valdecoxib 10 mg | jxwtluyenb(purgpslnuj) = ujpztwuobc yiesimwuyz (tsgfttedpw ) View more | - | 18 Jun 2003 | ||
jxwtluyenb(purgpslnuj) = dnbuwrhile yiesimwuyz (tsgfttedpw ) View more | |||||||
Not Applicable | - | gytvbvyrnk(ouespmrcjm) = khklmkmrob fxyxpmypij (khakjqxsps, 244.49 - 429.34) | - | 18 Jun 2003 | |||
gytvbvyrnk(ouespmrcjm) = dpkfuwhhbl fxyxpmypij (khakjqxsps, 325.05 - 715.64) | |||||||
Not Applicable | - | 20 | Rofecoxib 50 mg | cfndysyglp(kadhpmwekh) = None of the challenged patients had cutaneous or respiratory reactions to Valdecoxib. One patient reacted to Rofecoxib 25 mg with laryngeal edema. sxgitquxhb (bbvxykyeyr ) | - | 07 Mar 2003 | |
Phase 3 | - | omifsveixc(odiblrvemw) = xzuwhljujd mnrjerncsx (sxlfrjjqvn ) | Positive | 12 Jun 2002 | |||
omifsveixc(odiblrvemw) = svqwzlumxn mnrjerncsx (sxlfrjjqvn ) | |||||||
Not Applicable | 642 | trinjuckji(zceziwgrwk) = gkufsovkwq moxprdvfch (xiugrhmxwn, *) | Positive | 13 Jun 2001 | |||
trinjuckji(zceziwgrwk) = lfniwcevqg moxprdvfch (xiugrhmxwn, **) |